8-K: LENSAR Reports Strong Q4 and Full Year 2024 Results, Driven by ALLY Robotic Cataract Laser System

LENSAR announces a 38% increase in Q4 revenue and a 27% increase in full-year revenue, driven by strong ALLY system placements and procedure volume growth.

Summary

• LENSAR reported its fourth quarter and full year 2024 financial results, showcasing significant growth.
• In Q4 2024, the company placed 31 ALLY robotic cataract laser systems, bringing the total installed systems to approximately 385, a 26% increase year-over-year.
• Fourth quarter revenue increased by 38% to $16.7 million compared to $12.1 million in Q4 2023.
• Full-year revenue reached $53.5 million, a 27% increase from $42.2 million in 2023.
• Recurring revenue exceeded $40 million for the full year, representing a 23% increase over the previous year.
• Worldwide procedure volumes grew by 24% to nearly 170,000 in 2024, with U.S. procedure volumes increasing by 21%.
• The company's share of the U.S. procedure market reached over 20% for the first time.
• The net loss for the quarter was $18.7 million, or ($1.61) per share, compared to a net loss of $3.9 million, or ($0.35) per share, for the same period in 2023, primarily due to a change in warrant liability.
• The net loss for the year was $31.4 million, or ($2.73) per share, compared to a net loss of $14.4 million, or ($1.31) per share, in the previous year, also impacted by the change in warrant liability and an impairment of intangible assets.
• Adjusted EBITDA was $0.5 million for the quarter and ($0.3) million for the full year.
• The company anticipates accelerating topline revenue growth in 2025 and expects to achieve positive Adjusted EBITDA results.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth and increasing market share, but the increased net loss due to warrant liabilities tempers the overall sentiment.

Positives

• Significant revenue growth in both Q4 and full year 2024.
• Strong ALLY system placements and increasing installed base.
• Growth in recurring revenue, indicating increased utilization of existing systems.
• Increase in worldwide and U.S. procedure volumes.
• Expansion of U.S. procedure market share.
• Anticipated acceleration of revenue growth and positive Adjusted EBITDA in 2025.

Negatives

• Net loss increased significantly in both Q4 and full year 2024, primarily due to changes in warrant liability and an impairment of intangible assets.
• Selling, general, and administrative expenses increased, although partially offset by decreases in research and development expenses.

Risks

• The company's history of operating losses and the need to achieve and sustain profitability.
• The impact of global macroeconomic conditions on the business.
• The willingness of patients to pay the price difference for LENSAR's products compared to standard procedures.
• The ability to maintain and grow an effective sales and marketing organization and international distributor network.
• Future capital needs and the ability to raise additional funds on acceptable terms.
• The risk of material disruption to the supply or manufacture of systems or component parts.
• Competition from companies with longer operating histories and greater resources.
• Risks associated with marketing, selling, and leasing products in markets outside the United States.
• Exposure to the credit risk of customers.
• The ability to accurately forecast customer demand and manage inventory levels.
• The risk of inadequate coverage or reimbursement by government or third-party payors.
• The potential impact of product liability suits.
• Risks related to government regulation and intellectual property matters.

Future Outlook

The company anticipates accelerating topline revenue growth in 2025 beyond the 27% achieved in 2024 and expects to achieve positive Adjusted EBITDA results.

Management Comments

• 'The fourth quarter marked an incredibly strong conclusion to a successful year across all of LENSARs key operating metrics,' said Nick Curtis, President and CEO of LENSAR.
• Nick Curtis also stated that the company achieved its second consecutive quarter of both positive Adjusted EBITDA results and an increased total cash and investments balance.

Industry Context

LENSAR's growth in the robotic cataract surgery market reflects the increasing adoption of advanced technologies in ophthalmology. The company's focus on recurring revenue through procedure volume indicates a sustainable business model.

Comparison to Industry Standards

• While specific competitor data isn't provided, the report mentions that LENSAR's U.S. procedure market share exceeded 20% for the first time, suggesting it is gaining ground against competitors like Alcon, Johnson & Johnson Vision, and Bausch + Lomb in the cataract surgery market.
• The growth in ALLY system placements indicates a competitive advantage in the robotic cataract surgery segment, potentially driven by its compact design and AI-integrated software.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and potential for future profitability.
• Employees: Positive impact due to company growth and expansion.
• Customers: Positive impact due to advanced technology and improved surgical outcomes.
• Suppliers: Positive impact due to increased demand for components and systems.

Next Steps

• LENSAR management will host a conference call and live webcast on February 27, 2025, to discuss the fourth quarter and full year results and provide a business update.
• The company expects to continue to increase its selling and marketing expenses in 2025 to support anticipated continued growth in ALLY placements and recurring revenue.
• The company will file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the SEC.

Key Dates